<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2021.111002</article-id><article-id pub-id-type="publisher-id">WJCR-39692</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20210100000_36229921.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  SBRT联合TACE治疗原发性肝癌伴门静脉癌栓的疗效分析
  Effect of SBRT Combined with TACE on Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杜</surname><given-names>海峰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卞</surname><given-names>晓山</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>武警山东省总队医院，肿瘤科，山东 济南</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>8</fpage><lpage>11</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨立体定向体部放射治疗(SBRT)联合肝动脉介入栓塞化疗(TACE)治疗不能手术的原发性肝癌伴门静脉癌栓的临床疗效。方法：2012年11月至2018年9月原发性肝癌伴门静脉癌栓患者62例均采用体部伽玛刀联合TACE治疗，TACE 1~2次，体部伽玛刀局部照射癌栓4~9 Gy/次，隔日治疗5~10次，总剂量35~54 Gy (中位38 Gy)。结果：全部患者均完成治疗。10例(16.1%)癌栓完全缓解，21例(33.9%)部分缓解，25例(40.3%)稳定，6例(9.7%)进展，总有效率(CR + PR + NC) 56例(90.3%)；1、2和3年生存率分别为30.6%、16.1%和3.2%，中位生存期12.8个月。结论：SBRT联合TACE治疗原发性肝癌伴门静脉癌栓有效提高了患者生存质量，延长了生存期。
    Objective: To investigate the clinical effect of body gamma knife combined with hepatic arterial chemoembolization (TACE) in the treatment of primary hepatic carcinoma with portal vein tumor thrombus. Methods: From November 2012 to September 2018, 62 patients with primary liver cancer and portal vein tumor Thrombi were treated with body gamma knife combined with TACE, TACE 1~2 times, body gamma knife local irradiation 4~9 Gy per time, and the total dose was 35~54 Gy (median dose was 38 Gy). Results: All patients completed the treatment course. 10 patients (16.1%) tumor thrombus was completely relieved, 21 patients (33.9%) had partial remission, 25 cases (40.3%) were stable, 6 cases (9.7%) increased, and the total effective rate (CR + PR + NC) was 56 (90.3%); 1, 2 and 3 year survival rates were 30.6%, 3.2% and 16.1%, respectively, and the median survival was 12.8 months. Conclusion: SBRT combined with TACE in the treatment of primary liver cancer with portal vein tumor thrombus can effectively improve the quality of life and prolong the survival time of patients. 
  
 
</p></abstract><kwd-group><kwd>原发性肝癌，门静脉癌栓，体部伽玛刀，肝动脉介入栓塞化疗，疗效, Primary Liver Cancer</kwd><kwd> Portal Vein Tumor Thrombus</kwd><kwd> Body Gamma Knife</kwd><kwd> Hepatic Arterial 
Chemoembolization</kwd><kwd> Curative Effect</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨立体定向体部放射治疗(SBRT)联合肝动脉介入栓塞化疗(TACE)治疗不能手术的原发性肝癌伴门静脉癌栓的临床疗效。方法：2012年11月至2018年9月原发性肝癌伴门静脉癌栓患者62例均采用体部伽玛刀联合TACE治疗，TACE 1~2次，体部伽玛刀局部照射癌栓4~9 Gy/次，隔日治疗5~10次，总剂量35~54 Gy (中位38 Gy)。结果：全部患者均完成治疗。10例(16.1%)癌栓完全缓解，21例(33.9%)部分缓解，25例(40.3%)稳定，6例(9.7%)进展，总有效率(CR + PR + NC) 56例(90.3%)；1、2和3年生存率分别为30.6%、16.1%和3.2%，中位生存期12.8个月。结论：SBRT联合TACE治疗原发性肝癌伴门静脉癌栓有效提高了患者生存质量，延长了生存期。</p></sec><sec id="s2"><title>关键词</title><p>原发性肝癌，门静脉癌栓，体部伽玛刀，肝动脉介入栓塞化疗，疗效</p></sec><sec id="s3"><title>Effect of SBRT Combined with TACE on Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus<sup> </sup></title><p>Haifeng Du, Xiaoshan Bian</p><p>Oncology Department, The Armed Police Forces Hospital of Shandong, Jinan Shandong</p><p><img src="//html.hanspub.org/file/2-2150202x4_hanspub.png" /></p><p>Received: Dec. 9<sup>th</sup>, 2020; accepted: Jan. 1<sup>st</sup>, 2021; published: Jan. 11<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/2-2150202x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the clinical effect of body gamma knife combined with hepatic arterial chemoembolization (TACE) in the treatment of primary hepatic carcinoma with portal vein tumor thrombus. Methods: From November 2012 to September 2018, 62 patients with primary liver cancer and portal vein tumor Thrombi were treated with body gamma knife combined with TACE, TACE 1~2 times, body gamma knife local irradiation 4~9 Gy per time, and the total dose was 35~54 Gy (median dose was 38 Gy). Results: All patients completed the treatment course. 10 patients (16.1%) tumor thrombus was completely relieved, 21 patients (33.9%) had partial remission, 25 cases (40.3%) were stable, 6 cases (9.7%) increased, and the total effective rate (CR + PR + NC) was 56 (90.3%); 1, 2 and 3 year survival rates were 30.6%, 3.2% and 16.1%, respectively, and the median survival was 12.8 months. Conclusion: SBRT combined with TACE in the treatment of primary liver cancer with portal vein tumor thrombus can effectively improve the quality of life and prolong the survival time of patients.</p><p>Keywords:Primary Liver Cancer, Portal Vein Tumor Thrombus, Body Gamma Knife, Hepatic Arterial Chemoembolization, Curative Effect</p><disp-formula id="hanspub.39692-formula9"><graphic xlink:href="//html.hanspub.org/file/2-2150202x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2150202x7_hanspub.png" /> <img src="//html.hanspub.org/file/2-2150202x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>原发性肝癌属于消化系统很常见的一种恶性肿瘤，而且门静脉癌栓也是影响肝癌预后的重要因素 [<xref ref-type="bibr" rid="hanspub.39692-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39692-ref2">2</xref>]。立体定向体部放射治疗(Stereotactic Body Radiotherapy, SBRT)是用射线抑制和杀灭癌细胞的一种治疗方法，具有很高的生物学效应，对不能手术的中晚期原发性肝癌或者拒行手术者达到缓解压迫、止痛的效果 [<xref ref-type="bibr" rid="hanspub.39692-ref3">3</xref>]。肝动脉介入化疗栓塞术(Transcatheter Arterial Chemoembolization, TACE)是原发性肝癌非手术治疗的首选方法，阻断肿瘤血供且肝癌局部获得高浓度化疗药物，将肿瘤凝固坏死。自2012年11月至2018年9月SBRT联合TACE治疗62例原发性肝癌伴门静脉癌栓患者，现回顾性分析其治疗效果。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 临床资料</title><p>62例患者平均年龄为56岁(35~79岁)，男性57例、女性5例，均接受SBRT联合TACE治疗，无其他治疗，其中病理诊断为肝细胞癌18例(29.0%)，胆管细胞癌2例(3.2%)。44例(70.9%)有典型的影像学表现和AFP &gt; 400 μg/L，另AFP &lt; 400 μg/L者9例(14.5%)。所有患者入组前均签署治疗知情同意书，本研究获得武警山东省总队医院伦理委员会批准。</p></sec><sec id="s6_2"><title>2.2. TACE方法</title><p>行股动脉穿刺，经肝动脉灌注顺铂40~60 mg、阿霉素20~30 mg或表阿霉素20 mg、吉西他滨1000 mg化疗等化疗药物，及碘化油10~20 ml栓塞。根据病人情况1~2个月介入治疗1~2次。</p></sec><sec id="s6_3"><title>2.3. SBRT方法</title><p>常规行0.3 cm或0.5 cm层厚的全腹部增强CT扫描定位，制定体部伽玛刀治疗计划，病灶直径 &lt; 3 cm，70%~80%等剂量曲线包绕靶区，单次剂量7~9 Gy，隔日治疗5~6次，总剂量36~42 Gy；直径3~5 cm者，60%~70%等剂量曲线包绕靶区，单次剂量5~8 Gy，隔日治疗5~8次，总剂量40 Gy；直径 &gt; 5cm，50%~60%等剂量曲线包绕靶区，单次剂量4~6 Gy，隔日治疗7~10次，总剂量40~42 Gy。</p></sec><sec id="s6_4"><title>2.4. 疗效评价</title><p>治疗2个月后通过CT图像观察病灶退缩情况 [<xref ref-type="bibr" rid="hanspub.39692-ref4">4</xref>]：完全缓解(CR)病灶完全消失，至少维持4周以上；部分缓解(PR)病灶减小50%以上，维持4周以上无新病灶出现；无变化(NC)病灶缩小不到50%或增大不超过25%，无新病灶出现；恶化(PD)病灶增大25%以上或出现新病灶；以CR + PR + NC为总有效率。</p></sec><sec id="s6_5"><title>2.5. 毒性评价</title><p>主要是消化道副反应、肝功能损害以及骨髓抑制反应等。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 治疗效果</title><p>62例患者中10例(16.1%)癌栓完全缓解，21例(33.9%)部分缓解，25例(40.3%)稳定，6例(9.7%)进展，总有效率(CR + PR + NC)56例(90.3%)；1、2和3年生存率分别为30.6%、16.1%和3.2%，中位生存期12.8个月。58例AFP阳性者下降28例(48.2%)，稳定13例(22.4%)，上升17例(29.4%)。</p></sec><sec id="s7_2"><title>3.2. 毒副作用</title><p>治疗期间未见严重并发症及不良反应。40例(64.5%)患者主要为乏力、食欲不振、恶心等症状，经临床对症处理好转；转氨酶升高者10例(16.1%)，经过保肝治疗好转；6例消化道出血者4例治疗后症状缓解，2例死亡；35.5% (22/62)的患者出现I + II级骨髓抑制反应，经治疗后恢复正常。</p></sec><sec id="s7_3"><title>3.3. 生存质量</title><p>80.6% (50/62)的患者上腹部不适和腹涨症状明显缓解，食欲改善；33例黄疸患者有72.7% (24/33)皮肤黄染消退及黄疸指数下降；26例腹水总改善率为69.2% (18/26)，有6例腹水消退、12例减轻、8例腹水加重。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>肝癌的恶性程度比较高，容易发生转移，肝癌的转移途径主要是血行转移，如果门静脉分支受侵犯，临床症状表现影响不是很大，但癌种侵犯到门静脉主干，就会导致门脉高压会加速肿瘤的全身扩散，临床表现有反复出现的消化道出血、肝性脑病，出现腹水不易消退。肝癌的镜下门静脉癌栓发生率高达66.2%~90.0% [<xref ref-type="bibr" rid="hanspub.39692-ref5">5</xref>]，当原发性肝癌侵犯门静脉并形成癌栓时，标志着肿瘤已属晚期，手术切除率低，预后差。</p><p>深圳玛西普公司的GMBS型SBRT装有25枚钴源，形成直径分别为15 mm、30 mm、50 mm不同焦点的高品质剂量场 [<xref ref-type="bibr" rid="hanspub.39692-ref6">6</xref>]，是一种融立体定向技术、放射外科技术于一体，辅助现代计算机技术，以治疗实体肿瘤为主的立体定向放射外科设备。SBRT利用伽玛射线几何聚焦原理，在精确的立体定向下，将经过规划的大剂量伽玛射线集中照射在预选靶点上，致死性的摧毁靶区组织，达到类似外科手术切除的效果 [<xref ref-type="bibr" rid="hanspub.39692-ref7">7</xref>]。由于靶点区域放射剂量场梯度较大，既可以达到靶区内总剂量是致死剂量又可以使靶区外正常组织不受伤害，SBRT亦是分次照射，且照射后的水肿有一定的缓冲，所以照射较大肿瘤风险不大 [<xref ref-type="bibr" rid="hanspub.39692-ref8">8</xref>]。从我们的治疗结果看较大肿瘤经治疗后亦有一定缓解率。</p><p>TACE通过栓塞肝动脉，切断肝癌的血供，使肿瘤缺血、缺氧，抑制肿瘤生长甚至可以达到肿瘤坏死目的，并且在栓塞的药物中混有化疗药，可以进一步实现对肿瘤的打击 [<xref ref-type="bibr" rid="hanspub.39692-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.39692-ref10">10</xref>]。在具体操作上个体化、大剂量的TACE治疗可明显提高疗效，降低肝癌体积并在短期内改善患者病情 [<xref ref-type="bibr" rid="hanspub.39692-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.39692-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.39692-ref13">13</xref>]。本人经验合理的进行TACE并配合外放疗可明显降低复发转移风险，从文中治疗结果看SBRT配合TACE的毒副反应较轻，并发症少，无严重放射性肝损伤发生，部分患者出现一些不适症状经对症处理完成全程治疗，62例患者总有效率有90.3%，中位生存期延长到12.8个月，生活质量改善率更达到80.6%。</p><p>综上所述，SBRT联合TACE的治疗方法对肝癌伴门静脉癌栓患者耐受性良好，提高了生活质量，加大了生存期，特别适用于不能进行肝肿瘤切除的中晚期患者 [<xref ref-type="bibr" rid="hanspub.39692-ref13">13</xref>]，其远期疗效有待进一步分析。</p></sec><sec id="s9"><title>文章引用</title><p>杜海峰,卞晓山. SBRT联合TACE治疗原发性肝癌伴门静脉癌栓的疗效分析Effect of SBRT Combined with TACE on Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus[J]. 世界肿瘤研究, 2021, 11(01): 8-11. https://doi.org/10.12677/WJCR.2021.111002</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39692-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">张学成, 贺选, 王永锋, 等. 肝动脉栓塞化疗联合立体定向放射治疗原发性肝癌的疗效分析[J]. 现代肿瘤医学, 2016, 24(21): 3437-3440.</mixed-citation></ref><ref id="hanspub.39692-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">朱中山, 严文辉, 彭新茂, 等. TACE联合立体定向放疗对肝癌伴门静脉癌栓患者预后的影响[J]. 实用癌症杂志, 2014, 29(6): 681-683.</mixed-citation></ref><ref id="hanspub.39692-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">陈亚平, 姜晓晓, 蒋冠, 等. TACE联合SBRT治疗原发性肝癌的Meta分析[J]. 国际肿瘤学杂志, 2015, 42(3): 182-187.</mixed-citation></ref><ref id="hanspub.39692-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">李玉, 杨海山. 肿瘤立体定向放疗与介入治疗肝癌[M]. 北京: 人民军医出版社, 2004: 287-307.</mixed-citation></ref><ref id="hanspub.39692-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">吴沛宏, 黄金华, 罗鹏飞, 等. 肿瘤介入诊疗学[M]. 北京: 人民军医出版社, 2005: 625-664.</mixed-citation></ref><ref id="hanspub.39692-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">孙守歧, 李宏斌. 体部伽玛刀治疗原理与临床应用[M]. 成都: 四川大学出版社, 2001: 515.</mixed-citation></ref><ref id="hanspub.39692-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">赵永生, 李平英, 李太平. 体部伽玛刀治疗98例原发性肝癌的疗效分析[J]. 中华全科医学, 2012, 10(5): 714-716.</mixed-citation></ref><ref id="hanspub.39692-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">党亚正, 王国栋, 陆婉玲, 等. 体部伽玛刀联合介入化疗栓塞治疗中晚期肝癌的meta分析[J]. 西部医学, 2014, 26(4): 430-434.</mixed-citation></ref><ref id="hanspub.39692-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">陈樱, 朱俊, 张火俊, 等. 射波刀联合TACE治疗原发性肝癌108例[J]. 世界华人消化杂志, 2014, 22(14): 2039-2044.</mixed-citation></ref><ref id="hanspub.39692-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">陈一兴, 曾昭冲, 孙菁, 等. 肝细胞肝癌经动脉化疗栓塞后行立体定向放疗的初步疗效观察[J]. 中国临床医学, 2017, 24(2): 224-228.</mixed-citation></ref><ref id="hanspub.39692-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">王磊, 咸玉涛, 杨正强, 等. 不同治疗方案对晚期肝细胞性肝癌预后的影响及因素分析[J]. 中华介入放射学电子杂志, 2018, 6(2): 104-108.</mixed-citation></ref><ref id="hanspub.39692-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">康军, 齐乃新, 王天权, 等. 三维适形放疗联合肝动脉化疗栓塞治疗不能手术的原发性肝癌的疗效研究[J]. 现代肿瘤医学, 2013, 21(8): 1834-1836.</mixed-citation></ref><ref id="hanspub.39692-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">林海敏, 孔玲玲, 于金明. 肝细胞癌外照射放疗的研究进展[J]. 中国肿瘤临床, 2018, 45(5): 260-264.</mixed-citation></ref></ref-list></back></article>